Targeted Medical Pharma, Inc.
TRGM · OTC
12/31/2015 | 9/30/2015 | 6/30/2015 | 3/31/2015 | |
|---|---|---|---|---|
| Market Cap | $0 | $0 | $3 | $5 |
| - Cash | $0 | $0 | $0 | $0 |
| + Debt | $5 | $5 | $5 | $5 |
| Enterprise Value | $6 | $6 | $8 | $10 |
| Revenue | $1 | $2 | $1 | $1 |
| % Growth | -17.5% | 16.4% | 25.7% | – |
| Gross Profit | $1 | $1 | $1 | $1 |
| % Margin | 60.2% | 68.2% | 60.2% | 48.4% |
| EBITDA | -$0 | $0 | -$0 | -$1 |
| % Margin | -24.3% | 5.1% | -16.5% | -113% |
| Net Income | -$1 | -$0 | -$1 | -$2 |
| % Margin | -45.1% | -15.2% | -40.7% | -157.2% |
| EPS Diluted | -0.021 | -0.01 | -0.02 | -0.06 |
| % Growth | -114% | 50% | 66.7% | – |
| Operating Cash Flow | $0 | $0 | -$0 | -$1 |
| Capital Expenditures | $0 | $0 | $0 | -$0 |
| Free Cash Flow | $0 | $0 | -$0 | -$1 |